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Salam Alkindi1,2*, Ikhlas Al-Busaidi1, Bushra Al-Salami1, Samir Raniga3, Anil pathare  1 & 
Samir K. Ballas4
Acute chest syndrome (AcS) is a major complication of sickle cell anaemia (ScA) and a leading cause 
for hospital admissions and death. We aimed to study the spectrum of clinical and laboratory features 
of AcS and to assess the predisposing factors and predictors of severity. A retrospective case-control 
cohort was studied by retrieving patient information from electronic medical records after ethical 
approval. One hundred adolescents and adults with SCA and hospital admissions for ACS were identified 
through the discharge summaries, along with 20 additional patients presenting with VOC, but without 
ACS (controls). Among the patients with ACS, fever (>38.5 °C), reduced oxygen saturation (<95) and 
asplenia significantly differed when compared to those of controls (p < 0.05, chi-squared test). The 
degree of severity was reflected in the use of non-invasive ventilation (NIV), simple and exchange 
transfusions, and the presence of bilateral pleural effusions and multi-lobar atelectasis/consolidation, 
which were significantly higher in the cases with ACS than in the controls. Lower haemoglobin (Hb) 
and high WBC counts were also significantly different between the two groups (p < 0.05, Student’s t 
test). Using logistic regression, our study further demonstrated that asplenia, fever, and reduced O2 
saturation, along with low Hb and leukocytosis, were important predictors for the development of ACS.
Sickle cell anaemia (SCA) is an autosomal recessive disorder characterized by a point mutation in codon 6 of the 
beta globin chain, where glutamic acid is replaced by valine, resulting in the formation of HbS with varied clinical 
manifestations1. The abnormal Hb is insoluble and polymerizes when exposed to low O2 tension, leading to the 
major clinical manifestations of SCA, including recurrent vaso-occlusive crisis (VOC), predisposition to infec-
tions and reduced red cell survival with anaemia2.
Sickle cell disease (SCD) is prevalent in sub-Saharan Africa and the Indian sub-continent, but human pop-
ulation mobility has spread the disorder throughout Europe, Asia and the Americas3,4. SCD is highly prevalent 
in Oman, with an estimated sickle cell gene frequency of 5.8% and a prevalence of sickle cell traits and SCA in 
Omani children of 4.8% and 0.3%, respectively5,6. It is thus estimated that one neonate of every 323 newborns in 
Oman has SCA6.
Acute chest syndrome (ACS) is defined as the presence of fever and/or new respiratory symptoms accom-
panied by the presence of a new pulmonary infiltrate on chest X-ray and is one of the most important causes 
of death and the second most common cause of hospitalization in SCA patients7. In a retrospective study, ACS 
was found to be responsible for 69.6% of SCA ICU admissions and was associated with a 16% mortality rate7. 
Furthermore, ACS is associated with a high risk of sickle cell-related mortality and morbidity, including pro-
longed hospitalization8. Although the aetiology of ACS is multifactorial, the Cooperative Study of Sickle Cell 
Disease (CSSCD) in the United States identified several aetiological factors, including infections (bacterial, viral 
and others), thrombosis, fat and pulmonary embolism, but in 50% of the cases, a clear aetiology could not be 
identified9. Furthermore, in the same study, high Hb, low HbF and high WBC counts during steady state were 
identified as risk factors for the development of ACS. It is also well known that many patients with SCA develop 
ACS after being admitted to the hospital9. Styles et al.10 observed that secretory phospholipase A2 (sPLA2) 
demonstrated a 67% specificity with 100% sensitivity to predict impending ACS in the patients they studied. This 
observation was further substantiated by Ballas et al.11 in 80% of SCA patients in their study. However, Styles et al., 
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in a more robust randomized study design, demonstrated a 71% specificity with 73% sensitivity, although the pos-
itive predictive value of sPLA2 was only 24%12. Unfortunately, the test is not yet available commercially. Therefore, 
the aim of this study was to evaluate the clinical and laboratory features of patients with ACS compared to patients 
with simple VOC and to assess the risk factors predisposing the development of ACS and potential predictors of 
its severity.
Materials and Methods
This is a single institution case-control cohort study of SCA patients, who were admitted with ACS between July 
2009 and June 2017 at our institution. A protocol was submitted to the Medical Research and Ethics Committee 
(MREC) to collect relevant details of consecutive cases from the medical records of patients who were admitted 
for ACS. All patients were Omani Arabs, above 15 years of age, with SCA (HbSS and HbSβ°), whereas other SCD 
subtypes, such as SD, SC, and SE, were excluded. Ninety-two SCA patients (100 episodes) were identified through 
the discharge summaries as having had ACS, and 20 SCA patients with simple VOC (20 episodes) who did not 
have ACS were used as the controls during the same time frame. The controls had an acute episode of severe pain 
in spite of the administration of analgesic medication and needed admission without any respiratory symptoms. 
These controls were selected consecutively in a 1:5 proportion during the same time frame as the enrolment of 
cases. Acute chest syndrome was defined as patients presenting with fever and/or respiratory symptoms, accom-
panied by new infiltrates on the chest radiograph. All methods were carried out in accordance with relevant local 
guidelines and regulations. The MREC approval (MREC #1333) was for a retrospective data collection and anal-
ysis; hence, individual patient consent was not required/mandated by the MREC.
The study evaluated clinical and laboratory parameters, including the vital signs such as heart rate, blood 
pressure, respiratory rate and pulse oximetry O2 saturation, for both groups of patients throughout the whole 
period of admission. Other clinical parameters that were studied included fever, chest/back pain, cough, wheez-
ing, crepitation and use of non-invasive ventilation (NIV). The laboratory parameters included Hb, HbF, retic-
ulocyte count, WBC count, platelet count, serum LDH, AST, ALT, serum bilirubin, serum creatinine, and CRP. 
Blood culture studies and the use of hydroxyurea (HU) and simple and exchange transfusion were also recorded. 
Radiological investigations recorded findings using chest X-rays, abdominal ultrasounds and chest CT scans.
Statistical analysis. The Statistical Package for Social Science (IBM SPSS, USA ver.23) was used to analyse 
the collected data. Normally distributed data were characterized as means with standard deviations, whereas data 
that were skewed [i.e., not normally distributed] were characterized as medians with interquartile ranges (IQRs) 
for continuous variables and as percentages and frequencies for categorical variables. The chi-squared test was 
used to study the statistical significance of qualitative variables, whereas Student’s t test was used to study the 
differences in the quantitative parameters between the cases and controls. Logistic regression with odds ratios 
and 95% confidence intervals (CIs) was performed to ascertain the effectiveness of the predictors of ACS. A 
p-value < 0.05 was considered statistically significant.
Results
Although there was a similar frequency of males in the cases and controls, males tended to suffer from ACS at an 
earlier median age than females (27 years compared to 31 years in females), but this was not statistically significant. 
History of previous ACS and hydroxyurea therapy was also similar between the two groups (Table 1).
Fever, crepitation and reduced O2 saturation by pulse oximetry were significantly abnormal in the cases with 
ACS (p < 0.05, chi-squared test). This was also reflected in the significantly higher odds ratios in the cases com-
pared to the controls (p < 0.05). Radiologically, abdominal ultrasound demonstrated a significantly higher degree 
of asplenia in the cases than in the controls (p < 0.05, chi-squared test). Pleural effusions, positive chest X-rays 
and CT scans of the chest as well as multilobar atelectasis were significantly greater in the cases than in the control 
(p < 0.05, chi- squared test).
Complete blood counts showed that Hb nadirs and maximal WBC counts showed a statistically significant 
difference between the two groups (p < 0.05, Student’s t test) with logistic regression analysis also confirming 
the significance (Table 2). HbF levels did not show any significant differences between the cases and controls. 
Furthermore, among the biochemical parameters, although serum CRP, serum total bilirubin, and serum LDH 
levels were elevated, they did not reach statistical significance (Table 1).
The blood cultures were positive in 4% of the cases compared to none in the controls. Furthermore, the use of 
NIV was reported in 16.3% of the cases compared to none in the controls.
Sixty-three percent of patients in the case group received simple blood transfusions compared to 20% in 
the control group, whereas exchange transfusions were given in 66.3% of ACS patients compared to 10% of the 
controls (p < 0.05, chi-squared test). The transfusions were based on the clinical evaluations and therapeutic 
decisions of the treating physicians. Only one death was recorded in the ACS patients compared to none in the 
control group.
Discussion
SCA is the most prevalent hereditary haemoglobin disorder in Oman5,6,12,13. Furthermore, ACS is the leading 
cause of death among patients with SCA7–9. It is characterized by acute onset of chest pain, associated with 
tachypnea, fever, reduced oxygen saturation, dyspnea, cough, elevated WBC counts and not infrequently, with 
a decreased Hb level and new infiltrates on chest X-ray. Many patients with SCA are admitted with VOCs and 
progress to develop symptoms and signs of ACS12, as was observed in this study.
Our aim was to study the risk factors that lead to the development of ACS, as determining the risk factors 
will help in identifying patients at risk early, thereby directing special attention towards them to prevent adverse 
outcomes. We observed that patients were more likely to develop ACS if they were older and female compared to 
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the control cohort admitted with a typical VOC. ACS is more common in children, but our study only included 
adolescents and adult patients. It is interesting that the median age of the study group was older than that of the 
control group, although not statistically significant. A previous history of ACS is a known potential risk factor, 
and it was seen in 58.7% of the ACS group; the mortality in this group was notably low (1.1%).
It is also known that males are at an increased risk for VOC compared to females14–16. Our study showed 
findings similar to these previously reported observations that ACS was more common among men than women. 
Parameters Cases (92) Controls (20) P value
Demography
Median age in years (IQR) 28(7.75) 26(6.25) 0.432#
Sex, Total cases, n, M: F 63:29 12:8
Median age in years, males (IQR) 27(7) —
Median age in years, females (IQR) 31(5) —
Clinical Features:
Prior ACS, n(%) 54(58.7) 11(55) 0.761#
HU therapy, n(%) 51(55.4) 10(50) 0.634#
Chest/Back pain, n(%) 83(90.2) 15(75) 0.062#
Fever [>37.80°C], n(%) 81(88) 13(65) 0.01#
Cough, n(%) 38(41.3) 6(30) 0.319#
Tachycardia [>100], n(%) 74(80.4) 14(70) 0.296#
Hypotension [<80], n(%) 71(77.2) 14(70) 0.542#
Tachypnea [>25], % 25(27.2) 1(5) 0.03#
Reduced Pulse oximetry
O2 saturation [<95], n(%) 67(72.8) 5(25) 0.0001#
Crepitations, n(%) 52(56.5) 0 0.000#
Wheeze, n(%) 10(10.9) 0 0.121#
Radiological Findings:
Asplenia, n(%) 51(55.4) 3(15) 0.001#
Pleural effusion n(%) 76(82.6) 0 0.000#
On X-ray chest, Mild n(%) 64(84.2)
Moderate n(%) 12(15.8)
On CT Scan, n(%) 49(53.3)
Multilobar atelectasis on CT scan, n(%) 83(90.2) 0 0.000#
Multilobar atelectasis on X Rays, n(%) 56(60.8) 0
Laboratory Parameters:
Median Hb nadir, g/L [95% CI] 7.8[7.6–8.1] 9.1[8.3–9.7] 0.0007$ 0.0007$
Median WBC count basal, X109/L [95% CI] 9.4[9.3–10.9] 7.4[7.1–9.7] 0.058$ 0.058$
Median WBC count Max, X109/L [95% CI] 17.6[16.8–19.3] 10.2[10.1–14.1] 0.0001$ 0.0001$
Median platelet count basal, X109/L [95% CI] 382[354–416] 343[226–459] 0.356$
Median platelet count nadir, X109/L [95% CI] 227[219–283] 175[180–391] 0.439$
Median retic count, % [95% CI] 5.5[5.3–8.0] 4.7[4.2–4.9] 0.206$
Median basal HbF, % [95% CI] 7.0[6.9–90.] 7.6[6.5–11.7] 0.441$
S.LDH at admission, u/L [RR 135–225] 745[542–872] 487[356–619] 0.131$
S.LDH max, u/L 1030[658–1287] 569[410–708] 0.09$
CRP at admission, mg/L [RR 0–5] 43[42–95.5] 71.5[49.7–104.7] 0.962$ 0.962$
CRP max, mg/L 180[153–203] 107[78.9–159.7] 0.066$ 0.066$
AST, u/L [RR 0–40] 49.7[49.3–66.4] 38.8[33.3–46.1] 0.127$ 0.127$
ALT, u/L [RR 0–41] 36.6[36.1–62.4] 30[25.2–46.9] 0.373$ 0.373$
S. bilirubin, μg/ml [RR 0–17] 44.2[44.1–66.6] 35[28.1–45.2] 0.056$
Interventions:
Use of NIV, n(%) 15(16.3) 0 0.047#
Abnormal blood cultures, n(%) 4(4.3) 0 0.872#
Simple blood transfusions, n(%) 58(63) 4(20) 0.016#
Exchange blood transfusions, n(%) 61(66.3) 2(10) 0.001#
Table 1. Comparison of demographic, clinical and laboratory parameters for SCA patients with ACS and 
without ACS. Key: #-chi-squared test; $-unpaired Student’s t test; IQR- interquartile range, RR- reference range, 
HU- hydroxyurea, ACS- acute chest syndrome, Hb- Haemoglobin, WBC- White blood cell count, NIV - non-
invasive ventilation, LDH-lactic dehydrogenase, CRP- C-reactive protein, AST- aspartate transaminase, ALT- 
alanine transaminase.
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However, the reason for this observation is not clear. Gladwin MT et al.16 reported slightly higher HbF levels in 
females compared to male SCA patients and concluded that this could be protective, forming the basis for gender 
differences in nitric oxide bioavailability. Ikuta T et al.17 have shown that nitric oxide is linked to transcriptional 
control of HbF and may explain the link between the two, i.e., the increased prevalence of ACS in males. They 
believe that oestrogen facilitates nitric oxide production and limits its consumption. We were not able to test this 
hypothesis as the use of hydroxyurea therapy was seen equally in both cases and controls and would be a con-
founding bias affecting the association between drug exposure and outcome.
Asthma is known to increase ACS, especially in children, and increase the risk of recurrence18,19; however, 
none of our ACS patients gave any previous history of childhood asthma. Furthermore, although wheezing was 
higher in the ACS group than in the control group, it did not reach statistical significance, and a larger sample 
may be necessary to see any correlation19.
Vichinsky EP et al. reported that many patients develop ACS following admissions with VOCs9. In this study, 
although many patients presented with features of ACS, some patients presented initially with back/chest pain, 
and these individuals were found to be more prevalent amongst those who progressed to ACS than among the 
controls in this study. However, this result did not reach statistical significance. Nevertheless, fever, hypoxia, and 
abnormal lung findings on clinical examination at admission are significant predictors for evolving to full blown 
ACS9. These findings also reemphasize the observations made in other studies, including the corporative study 
on SCA and others20,21.
Parameters
Odds 
Ratio 95% CI P value
Demography
Age 1.087 0.978 1.208 0.123
Sex (Male) 1.135 0.425 3.032 0.8
Clinical Features:
Prior ACS 1.067 0.615 1.851 0.753
HU therapy 1.109 0.605 2.032 0.658
Chest/Back pain, 3.074 0.899 10.68 0.074
Fever [>37.80°C], 3.965 1.316 11.85 0.014
Cough, 1.690 0.609 4.742 0.321
Tachycardia [>100], 1.366 0.678 2.774 0.389
Hypotension [<80], 1.013 0.988 1.039 0.098
Tachypnea [>25], 4.226 0.896 19.74 0.068
Reduced pulse oximetry
O2 saturation [<95], 8.111 2.689 24.47 0.000
Asplenia, 7.049 1.957 18.68 0.000
Laboratory Parameters:
Median Hb basal, 0.803 0.555 1.161 0.244
Median Hb nadir, 0.535 0.385 0.805 0.003
Median WBC count basal, 1.175 0.991 1.393 0.064
Median WBC count max, 1.236 1.098 1.392 0.000
Median platelet count basal, 1.002 0.998 1.005 0.353
Median platelet count nadir, 0.999 0.996 1.002 0.438
Median retic count, 1.190 0.897 1.579 0.229
Median basal HbF, 0.983 0.875 1.060 0.439
S.LDH at admission, 1.002 1.000 1.004 0.132
S.LDH max, 1.001 1.000 1.003 0.107
CRP at admission 1.000 0.994 1.007 0.964
CRP max 1.005 1.000 1.010 0.071
AST, u/L 1.024 0.995 1.054 0.103
ALT, u/L 1.010 0.990 1.031 0.331
S. bilirubin, 1.024 0.998 1.051 0.069
Interventions:
Simple blood transfusions, 8.514 2.310 31.375 0.001
Exchange blood 
transfusions, 31.571 4.031 247.26 0.001
Table 2. Logistic regression analysis with odds ratios for the demographical, clinical & laboratory parameters 
of SCA patients with ACS and without ACS. Key: HU- hydroxyurea, ACS- acute chest syndrome, Hb- 
Haemoglobin, WBC- white blood cell count, NIV- non-invasive ventilation, LDH-lactic dehydrogenase, CRP- 
C-reactive protein, AST- aspartate transaminase, ALT- alanine transaminase.
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As reported previously20,21, a higher WBC count at baseline predicted a higher risk of ACS and was also seen 
in our study. Furthermore, these patients demonstrated a further rise in WBC count associated with a consider-
able drop in haemoglobin from baseline and with significantly higher platelet counts, as these patients more fre-
quently progressed to ACS when compared to VOC patients in the control group. The reasons for the association 
between a high leukocyte count and ACS incidence are not clear, but may relate to the underlying inflammatory 
process. Castro O et al.20 reported that higher leukocyte counts correlated with higher mortality rates. Therefore, 
the association of leukocytosis with ACS incidence could reflect the fact that both high WBC counts and high 
ACS rates are more frequently seen in patients with severe SCD20. The rise in serum CRP and the drop in Hb 
levels may signify increased haemolysis, sequestration in the lung or possibly sepsis. Furthermore, although the 
baseline HbF was relatively high in both groups, it did not seem to exert any protective effect on this group of 
patients, contrary to results from previous studies20.
Our study demonstrated significantly high serum LDH in ACS patients on the day of admission. This was 
also observed in the CSSCD and the French study on ACS in adults with SCA20,22. Furthermore, there was a 
trend towards significance with rising serum LDH max and serum bilirubin, which had p values of 0.09 and 
0.05, respectively. This is consistent with the degree of haemolysis and underlying tissue necrosis, including bone 
marrow infarction, observed in these cases. Other biochemical parameters, such as serum AST and ALT, did not 
show any statistical significance in patients who had ACS.
There was a significantly higher prevalence of asplenia in the ACS group (55.4%) compared to the con-
trol group (15%). In view of the fact that HbF was similar in both groups, this is a significant observation. 
Furthermore, these asplenic patients are at an increased risk of sepsis and thrombosis, which may explain the ele-
vated WBC counts and serum CRP in the ACS group. Although only 4% of the ACS group showed culture-proven 
bacterial infection, all of our patients received empiric broad-spectrum antibiotics. Infection is a major cause of 
morbidity and mortality in patients with SCA9,19,21. Our data are also consistent with a previous prospective study 
suggesting that bacterial pneumonia is not frequent in adult episodes of ACS22. Furthermore, in the CSSCD study 
from the USA, only a few bacteria were detected in lung samples on bronchoscopy, considering that bronchos-
copy was invariably performed after empiric antibiotic administration, as is the universal practice20.
Radiological evaluation showed that the initial chest X-rays were normal in 21% of cases (data not shown), 
although they were abnormal in all the cases as ACS evolved in this group. Pleural effusions were seen in 76 
(82.6%) of the cases on their chest X-ray and in 49 (53.3%) on their CT scan. Among these 76 cases, 12 (15.8%) 
had moderately severe effusions, while 64 (84.2%) had mild effusions. Multilobar atelectasis was observed in 
60.8% and 90.2% of the cases on plain chest X-rays and CT scans, respectively. Not all patients had CT scans, as it 
is generally only requested in the most severe cases, which may explain the discrepancies in the findings between 
the two modalities.
Transfusions are often recommended for the treatment of ACS, and in a large American study9, transfusions 
were given in 75% of episodes; however, no controlled studies have been performed to evaluate the effect of trans-
fusion on lung function and mortality. Additionally, transfusion is not devoid of serious side effects, including 
pulmonary oedema, blood-borne infections, and alloimmunization23. Nonetheless, simple and exchange trans-
fusions are considered to be lifesaving in ACS patients as they improve oxygenation and reduce sickled RBCs and 
have other possible potential advantages. In our study, the majority of patients with ACS received simple (63% vs 
20% in the control) and/or exchange transfusions (66.3% vs 10% in control).
A total of 16.3% of our patients needed NIV/mechanical ventilation, which is indicative of increased disease 
severity in these patients. Importantly, another study from our institution showed that 69.6% of all SCA patients 
admitted to intensive care had ACS7. It was also reported that the need for inotropic support and mechanical 
ventilation was a predictor of mortality in these patients7. Previously, mechanical ventilation was found to predict 
mortality and the increased utilization of hospital resources18.
This study has some shortcomings, including being retrospective, being from a single institution, and having 
a relatively small sample size. Large prospective studies are needed to validate the role of these risk factors to 
estimate their predictive value. Validating and confirming these findings may form the basis for creating a score 
for patients with VOC who are likely to develop ACS during their initial assessment at the time of admission.
conclusion
Our study demonstrated that high fever, reduced O2 saturation, and asplenia were associated with a high proba-
bility for predicting ACS during VOC episodes. Additionally, a significant drop in Hb and leukocytosis were also 
important predictors for the development of ACS in this study. Pleural effusion on chest X-ray, multi-lobar con-
solidation on CT scans; NIV and simple/exchange transfusions indicated severity of ACS in the Omani patients 
in this retrospective chart review study.
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